Importance of preclinical investigations of the integration of capecitabine into polychemotherapy regimens.
Danesi
Romano
R
Division of Pharmacology and Chemotherapy, Department of Oncology, University of Pisa, Italy.
Bocci
Guido
G
Di Paolo
Antonello
A
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000069287:Capecitabine; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005260:Female; D005472:Fluorouracil / Q000494:pharmacology; D000077146:Irinotecan; D020714:Maximum Tolerated Dose; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D011799:Quinazolines / Q000494:pharmacology; D013876:Thiophenes / Q000494:pharmacology
D000970:Antineoplastic Agents; D011799:Quinazolines; D013876:Thiophenes; D003841:Deoxycytidine; D000069287:Capecitabine; D000077146:Irinotecan; C068874:raltitrexed; D005472:Fluorouracil; D002166:Camptothecin